Prominent IL-12 Production and Tumor Reduction in Athymic Nude Mice After Toxoplasma Gondii Lysate Antigen Treatment

Overview

Journal Korean J Parasitol

Specialty Parasitology

Date 2014 Dec 31

PMID 25548411

Citations 13

Authors

Kyoung-Ho Pyo

Bong-Kwang Jung

Chun-Feng Xin

You-Won Lee

Jong-Yil Chai

Eun-Hee Shin

Affiliations

Soon will be listed here.

Abstract

Toxoplasma gondii is an intracellular protozoan parasite that causes a Th1 cellular immunity. Our previous study showed that T. gondii lysate antigen (TLA) treatment in S180 tumor-bearing mice resulted in tumor reduction by suppressing CD31 expression, a marker of angiogenesis. In the present study, to investigate tumor suppressive effect of TLA under the absence of T lymphocytes, athymic nude mice were compared with euthymic mice in the anti-tumorigenic effect triggered by TLA in CT26 tumors. According to the results, intratumorally injected TLA reduced tumor growth and TIMP-1 level, a metastatic marker, in both euthymic and athymic mice. TLA treatment led to a sharp increase in IL-12 expression in serum cytokine profiling of athymic mice, and increased MyD88 signals in macrophages derived from the bone marrow, implying the activation of innate immunity. The selective induction of IL-12 by TLA treatment had an anti-tumorigenic effect.

Citing Articles

Association of Neuroblastoma (NB) SH-SY5Y Cells with Antibodies of Parasitic Origin (Anti- and Anti-).

Maravelez Acosta V, Garcia M, Patino Lopez G, Crisostomo Vazquez M, Franco Sandoval L, Eligio Garcia L Int J Mol Sci. 2025; 25(24.

PMID: 39769340 PMC: 11678856. DOI: 10.3390/ijms252413577.

Toxoplasma gondii-Derived Exosomes: A Potential Immunostimulant and Delivery System for Tumor Immunotherapy Superior to Toxoplasma gondii.

Zhao L, Sun Q, Wang C, Liu J, Yan X, Shao M Int J Nanomedicine. 2024; 19:12421-12438.

PMID: 39600411 PMC: 11590659. DOI: 10.2147/IJN.S483626.

Parasites revive hope for cancer therapy.

Eissa M, Salem A, El Skhawy N Eur J Med Res. 2024; 29(1):489.

PMID: 39367471 PMC: 11453045. DOI: 10.1186/s40001-024-02057-2.

Parasite-enhanced immunotherapy: transforming the "cold" tumors to "hot" battlefields.

Xie Y, Wang J, Wang Y, Wen Y, Pu Y, Wang B Cell Commun Signal. 2024; 22(1):448.

PMID: 39327550 PMC: 11426008. DOI: 10.1186/s12964-024-01822-4.

An Overview of the Dichotomous Role of Microbiota in Cancer Progression and Management.

Jain P, Mohapatra S, Farooq U, Hassan N, Aamir Mirza M, Iqbal Z Curr Cancer Drug Targets. 2024; 25(1):38-48.

PMID: 38409691 DOI: 10.2174/0115680096282503240124104029.

References

Del Rio L, Butcher B, Bennouna S, Hieny S, Sher A, Denkers E . Toxoplasma gondii triggers myeloid differentiation factor 88-dependent IL-12 and chemokine ligand 2 (monocyte chemoattractant protein 1) responses using distinct parasite molecules and host receptors. J Immunol. 2004; 172(11):6954-60. DOI: 10.4049/jimmunol.172.11.6954. View

Smyth M, Taniguchi M, Street S . The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol. 2000; 165(5):2665-70. DOI: 10.4049/jimmunol.165.5.2665. View

Egilmez N, Kilinc M . Tumor-resident CD8+ T-cell: the critical catalyst in IL-12-mediated reversal of tumor immune suppression. Arch Immunol Ther Exp (Warsz). 2010; 58(6):399-405. DOI: 10.1007/s00005-010-0097-7. View

Wurtz S, Schrohl A, Mouridsen H, Brunner N . TIMP-1 as a tumor marker in breast cancer--an update. Acta Oncol. 2008; 47(4):580-90. DOI: 10.1080/02841860802022976. View

Kim J, Jung S, Kim S, Kim T, Shin D, Lee J . Inhibition of Lewis lung carcinoma growth by Toxoplasma gondii through induction of Th1 immune responses and inhibition of angiogenesis. J Korean Med Sci. 2007; 22 Suppl:S38-46. PMC: 2694397. DOI: 10.3346/jkms.2007.22.S.S38. View

Sznol M, Lin S, Bermudes D, Zheng L, King I . Use of preferentially replicating bacteria for the treatment of cancer. J Clin Invest. 2000; 105(8):1027-30. PMC: 300839. DOI: 10.1172/JCI9818. View

Colombo M, Trinchieri G . Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002; 13(2):155-68. DOI: 10.1016/s1359-6101(01)00032-6. View

Wortis H . Immunological responses of 'nude' mice. Clin Exp Immunol. 1971; 8(2):305-17. PMC: 1712939. View

Yarovinsky F, Zhang D, Andersen J, Bannenberg G, Serhan C, Hayden M . TLR11 activation of dendritic cells by a protozoan profilin-like protein. Science. 2005; 308(5728):1626-9. DOI: 10.1126/science.1109893. View

10.

Weischenfeldt J, Porse B . Bone Marrow-Derived Macrophages (BMM): Isolation and Applications. CSH Protoc. 2011; 2008:pdb.prot5080. DOI: 10.1101/pdb.prot5080. View

11.

Sher A, Collazzo C, Scanga C, Jankovic D, Yap G, Aliberti J . Induction and regulation of IL-12-dependent host resistance to Toxoplasma gondii. Immunol Res. 2003; 27(2-3):521-8. DOI: 10.1385/IR:27:2-3:521. View

12.

Ring C . Cytolytic viruses as potential anti-cancer agents. J Gen Virol. 2002; 83(Pt 3):491-502. DOI: 10.1099/0022-1317-83-3-491. View

13.

Chen L, He Z, Qin L, Li Q, Shi X, Zhao S . Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity. PLoS One. 2011; 6(9):e24407. PMC: 3170332. DOI: 10.1371/journal.pone.0024407. View

14.

Whitworth J, Alvarez R . Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature. Expert Opin Biol Ther. 2011; 11(6):751-62. DOI: 10.1517/14712598.2011.566854. View

15.

Aliberti J, Serhan C, Sher A . Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J Exp Med. 2002; 196(9):1253-62. PMC: 2194099. DOI: 10.1084/jem.20021183. View

16.

Lim H, Lee S, Jung B, Kim M, Lee M, Nam H . Serologic survey of toxoplasmosis in Seoul and Jeju-do, and a brief review of its seroprevalence in Korea. Korean J Parasitol. 2012; 50(4):287-93. PMC: 3514419. DOI: 10.3347/kjp.2012.50.4.287. View

17.

Lehmann T, Marcet P, Graham D, Dahl E, Dubey J . Globalization and the population structure of Toxoplasma gondii. Proc Natl Acad Sci U S A. 2006; 103(30):11423-8. PMC: 1544101. DOI: 10.1073/pnas.0601438103. View

18.

Li D, Yu H, Xu T, Li J, Sun Y, Zhang W . Interleukin-12 gene modification exerts anti-tumor effects on murine mammary sarcoma cell line in vivo. Cell Mol Immunol. 2008; 5(3):225-30. PMC: 4651292. DOI: 10.1038/cmi.2008.28. View

19.

Hibbs Jr J, Lambert Jr L, Remington J . Resistance to murine tumors conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni. J Infect Dis. 1971; 124(6):587-92. DOI: 10.1093/infdis/124.6.587. View

20.

Lauw F, Caffrey D, Golenbock D . Of mice and man: TLR11 (finally) finds profilin. Trends Immunol. 2005; 26(10):509-11. DOI: 10.1016/j.it.2005.08.006. View